bid modified Rankin Scale (pmRS) score, TE and allergic event that occurred during the hospital stay. All events were classified by 3 reviewers as being 'related', 'probably related', 'possibly related', 'unlikely related' or 'not related' to treatment with PCC. To identify factors associated with TEs, logrank analyses were applied. Results: Two hundred and five patients were included. Median INR was 2.8 (interquartile range (IQR) 2.2-3.8) before and 1.3 (IQR 1.2-1.4) after PCC treatment and a median of 1,500 IU PCC (IQR 1,000-2,500) was administered. Nineteen TEs were observed (9.3%); none were classified 'related' but 9 were classified as 'possibly' or 'probably related' to PCC infusion (4.4%). One allergic reaction (0.5%), 'unlikely related' to PCC, was observed. In the whole cohort, PCC doses >2,000-3,000 IU, ICH volumes >40 ml, National Institute of Health Stroke Scale values >10 and a pmRS >2 were associated with the development of TEs (p = 0.031, p = 0.034, p = 0.050 and p = 0.036, respectively). Conclusions: Overall, INR reversal with PCC appears safe. Though
Introduction
Intracerebral hemorrhages (ICHs) represent the most feared complication of treatment with oral anticoagulants [1, 2] . About 10-18% of all ICH cases are associated with vitamin K antagonists (VKAs) [3, 4] , and with up to 54% of hematomas enlarging within the first hours after diagnosis, secondary hematoma growth in VKA-ICH is much more prevalent than in primary ICH (16%) [5, 6] . Moreover, hematoma growth in VKA-ICH is often prolonged in time [7] and mortality rates considerably exceed the rates of primary ICH (34 vs. up to 67%) [1, 2, [5] [6] [7] [8] [9] .
To prevent hematoma enlargement and to reduce the associated risk of an unfavorable outcome including death [10, 11] , guidelines recommend reversing the anticoagulatory effect of VKA in ICH patients as fast as possible [3, 10, [12] [13] [14] and current guidelines for VKA reversal in ICH recommend prothrombin complex concentrates (PCCs) combined with vitamin K over fresh frozen plasma (FFP) [15] . PCC normalizes the international normalized ratio (INR) more rapidly compared to FFP [14, [16] [17] [18] , a finding that has recently been confirmed impressively in patients with VKA-ICH as well [19] . Moreover, PCC does not require any serologic testing before administration and necessary infusion volumes are smaller compared to FFP [11, 20, 21] . Importantly, fast INR normalization appears to be associated with smaller hematoma expansion in VKA-ICH [19, 22] .
According to a large meta-analysis, the risk of thromboembolic events (TEs) after PCC infusion is low ( ∼ 1.8%), but indications for PCC treatment and sample sizes varied considerably between included studies [23] .
Data on TEs related to reversal treatment with PCC in patients with VKA-ICH are surprisingly rare. A recent study evaluating the prevalence of adverse events in a homogenous population with VKA-ICH reported 2 TEs in 27 patients (7.4%) within the first 3 days after therapy with PCC and another 5 TEs (18.5%) within 3 months [19] after PCC treatment.
Here, we aimed to determine the rate of TE and allergic event after treatment with PCC in a large consecutive cohort of patients with VKA-ICH.
Methods
Consecutive patients who were treated with PCC between December 2004 and June 2014 at the Departments of Neurology and Neurosurgery, Heidelberg University Hospital, Germany, were included into a prospective database. All patients with non-traumatic VKA-ICH entered the present observational analysis. Patients with ICH due to cerebral venous thrombosis, trauma, tumors, subarachnoid hemorrhages, secondary ICH after thrombolysis or hemorrhagic transformation, non VKA-related coagulopathies and patients that were (co-)treated with recombinant factor VIIa or FFP were excluded. All neurosurgical interventions (e.g., hematoma evacuation, ventricular or hematoma drainage) were recorded. Analyzed data were obtained retrospectively from the patients' charts.
Standard procedures for all patients at admission encompassed a clinical examination, documentation of basic demographic variables and cardiovascular risk factors and brain imaging (CT or MRI). Stroke severity was assessed using the National Institute of Health Stroke Scale (NIHSS). Moreover, standardized laboratory testing, including a full blood count, glucose, electrolytes, urea, creatinine, prothrombin time and calculation of the INR was performed at admission.
In accordance with current guidelines [10, 14] and local standardized procedures, VKA reversal with PCC was started as fast as possible after diagnosis of ICH in patients with an INR ≥ 1.5 until an INR <1.5 was achieved and coagulation tests were repeated after the end of PCC infusion in all patients. The time between symptom onset and first CT or MRI, leading to the diagnosis of ICH, and the time between diagnosis of ICH and successful INR reversal (INR < 1.5) were recorded.
The following 4-factor PCC products (i.e., PCCs containing factors II, VII, IX and factor VII [24] ) were used to reverse anticoagulation: Beriplex P/N 500 ® (CSL Behring GmbH, Marburg, Germany), Octaplex ® (Octapharma, Langenfeld, Germany) and PPSB-Human SD/Nano 600 ® (Octapharma, Langenfeld, Germany; online suppl. 448 electrocardiographic changes, troponin T elevations (>50 pg/ml) and results of cardiac catheterization were taken into consideration [25] . Deep vein thrombosis was diagnosed by typical clinical signs and/or imaging of the venous system. To diagnose pulmonary embolism (PE), clinical symptoms, vital parameters, ECG changes, blood gas analyses and imaging results were taken into consideration [26] . Ischemic strokes were diagnosed by clinical symptoms and the results of brain imaging [27] .
Allergic and anaphylactic reactions were diagnosed in case of new skin exanthemas, rush, pruritus, oro-lingual edema or sudden and otherwise unexplained abnormalities of the cardiorespiratory system [28] .
All events were reviewed by 3 reviewers (M.L., O.J.M. and T.R.) following the World Health Organization Collaborating Centre for International Drug Monitoring (Uppsala Monitoring Center) causality assessment system [29] . All events were subsequently categorized in consensus by the reviewers as being 'related', 'probably related', 'possibly related', 'unlikely related' or 'not related' to treatment with PCC.
ICH Enlargement and Clinical Outcome
ICH was classified according to its location into lobar, deep and infratentorial [30] . To quantify intraventricular hemorrhage, the modified Graeb score was applied [31] . Follow-up brain imaging (CT or MRI) to assess hematoma enlargement was conducted 20-36 h after the initial diagnosis or earlier in case of clinical deterioration. As previously described, planimetric volumetry was performed by the ABC/2 or, in case of irregularly shaped hematomas, by the ABC/3 formula [32, 33] . Substantial hematoma growth was defined as hematoma enlargement of ≥ 33.3% or 6 ml [34] between initial and follow-up brain imaging. The modified Rankin Scale (mRS) was used to report the functional status before ICH premorbid mRS (pmRS) and at discharge. Functional independence post ICH was defined in accordance with previous reports [19] as mRS values of 0-3.
The independent Ethics Committee of the medical faculty of the Heidelberg University approved the study, and the manuscript was developed according to the STROBE guidelines for reporting observational studies [35] .
Statistical Analysis
Most descriptive data are presented in relative frequencies, ordinal and continuous data as medians and interquartile ranges (IQRs). To test for normal distribution, the Kolmogorov-Smirnov test was applied. Depending on the scale level of variables, we used the Mann-Whitney U test for continuous, but not normally distributed variables and the chi-square test for categorical variables to explore differences between groups with regard to the presence of TEs and ICH enlargement. To test associations between INR values and ICH enlargement, Spearman correlations were applied. The time between symptom onset and diagnosis of ICH was categorized into the following intervals: <2, 2-4, 4-6, 7-12, 13-24 and >24 h. Based on a previous approach [36] , ICH volume at admission was categorized into 6 groups (<20 and ≥ 20 ml, <30 and ≥ 30 ml, <40 and ≥ 40 ml, <50 and ≥ 50 ml, <60 and ≥ 60 ml, <70 and ≥ 70 ml). To investigate associations of clinical characteristics and therapeutic variables on TEs, Kaplan-Meier and log rank analyses were used. To compare TE-distributions of different subgroups (e.g., dependent on PCC dosage, stroke severity), we used the log rank test and Kaplan-Meier plots to visualize the estimated survival curves. To distinguish between severe and light to moderate pre-stroke disability and stroke severity, pmRS and NIHSS values were dichotomized (pmRS: 0-2 and 3-5; NIHSS: 0-10 and 11-42) [37] . PCC dosages were included in Kaplan-Meier plots and log rank tests to test for dose-dependent incidences of TEs by using the following groups: ≤ 1,000 vs. >1,000 IU, ≤ 2,000 vs. >2,000 IU, ≤ 3,000 vs. >3,000 IU and ≤ 4,000 vs. >4,000 IU. A p value of ≤ 0.05 was considered statistically significant. Data analysis was performed using the Statistical Package for Social Sciences (SPSS) 22.0 for Windows (IBM, Armonk, USA).
Results

Patient and ICH Characteristics
Overall, we included 205 patients (c.f. online suppl. fig. 1 ). Basic demographic variables, cardiovascular risk factors and indications for oral anticoagulation are summarized in table 1 . The median age was 75 years (IQR 69- 449 80), 64.6% of patients were male and the median NIHSS at admission was 13 (IQR 6-22). The most common reason for oral anticoagulation was atrial fibrillation (69.3%), followed by deep vein thrombosis (9.3%) and mechanical heart valves (9.3%; table 1 ). Patients were hospitalized at our center for a median of 6 days (IQR 3-11). Most hematomas were localized in deep brain structures (n = 99; 48.3%). Lobar bleeds were observed in 72 patients (35.1%) and 28 (13.7%) suffered infratentorial hemorrhages. Pure intraventricular hemorrhages were diagnosed in 6 patients (2.9%).
INR Reversal
At admission, the median INR was 2.8 (IQR 2.2-3.8). A median dose of 1,500 IU PCC (IQR 1,000-2,500) was administered. One hundred and thirty-nine minutes after ICH diagnosis (median; IQR 89-241), the INR was reversed (INR <1.5) and a median INR of 1.3 was observed after completion of PCC treatment (IQR 1.2-1.4; p < 0.001).
Within 48 h after admission, 172 patients (83.9%) received LMWH for prevention of venous thromboembolism.
TE and Allergic Event
In total, 19 TEs (9.3%) and 1 allergic event (0.5%) were identified among the 205 patients (c.f. fig. 1 ). Ischemic strokes represented the most common type of TEs (7 of Importantly, none of the events was considered 'related' to treatment with PCC, but 2 of 19 TEs (10.5%) were categorized 'probably related' to the preceding PCC treatment (2 ischemic strokes), and 7 of 19 events (36.8%) were judged 'possibly related' to treatment with PCC (2 ischemic strokes, 2 MIs, 2 PEs and 1 deep vein thrombosis). All other events were rated as either 'unlikely related' (7 of 19; 36.8%) or 'not related' (3 of 19; 15.8%) to PCC treatment ( fig. 1 ) .
The observed allergic reaction was assessed 'unlikely related' to treatment with PCC; it followed cerebral angiography with iodine-containing contrast medium 4 days after PCC infusion.
Factors Associated with Any TE
Associations between demographic factors, clinical parameters and treatment-related factors with TEs that were observed are summarized in table 2 . Log rank analyses revealed that factors associated with TEs (n = 19) were PCC dosages between >2,000 and 3,000 IU (p = 0.031), severe strokes at admission (NIHSS scores >10; p = 0.050) and a pmRS of 3-5 (p = 0.016; table 2 ). Kaplan-Meier plots for PCC dosages and dichotomized NIHSS values are given in figure 2 . Because the assumption of proportional hazards was not fulfilled, Cox regression was not performed. 
Clinical Outcome and Association with TEs
In-hospital mortality was 27.8% (n = 57), and 22.0% (n = 45/205) of patients were functionally independent at discharge (mRS 0-3). Expectedly, mortality was higher in patients with hematoma growth (46.9%) compared to those without (13.4%; p < 0.001). Mortality rates did not differ between patients with and without TEs (40 vs. 26.8%; p = 0.190). Moreover, no difference with regard to the rate of functional independency was observed between patients with and without TEs (15.8 and 22.4% respectively; p = 0.530).
Discussion
The major findings of this study are that (1) TEs after PCC treatment were observed in 9.3% of patients but none were classified as 'related' to the treatment with PCC. (2) None of the TEs were classified as 'related' but TEs were considered 'possibly' or 'probably related' to treatment with PCC in 4.4% of patients. (3) In patients with PCC, dosages between >2,000 up to 3,000 IU TEs compared to lower dosages were observed. (4) Worse premorbid status and higher stroke severity were associated with TEs.
Faster restoration of coagulation and lower infusion volumes represent clear advantages of PCC compared to FFP in anticoagulation reversal in VKA-ICH patients [10, 11, 14, 16, 17, 19, 21] . Hence, PCC are widely used in this indication [22, 38] . However, despite the fact that PCC is frequently used in clinical routine, data on PCCrelated thromboembolic complications in patients with VKA-ICH are still limited [19, 39] .
In anticoagulation reversal with PCC not being limited to VKA-ICH patients, thromboembolic complications associated to PCC administration have been reported in 1.8% in a meta-analysis and in 0.0-7.3% [23, [39] [40] [41] [42] [43] among observational cohort studies and randomizedcontrolled trials that included patients with VKA-related bleedings or prior to urgent surgical procedures. Evaluating specifically VKA-ICH patients, a retrospective study with 30 VKA-ICH patients treated with PCC reported a TE rate of 10% [40] . In the Intracranial Hemorrhage Related to VKA trial [19] , 7.4% of patients within the PCC group (n = 27) suffered TEs during the first 3 days after treatment, and in 29.2% of patients, TEs were observed during the observational period of 90 days [19] . On the other hand, in ICH patients who did not have anticoagulation, venous thromboembolism has been reported in 1.9-19.8% [44] [45] [46] [47] .
We observed TEs in 9.3% of patients during the acute hospital stay. All the more, no event was classified 'related' to treatment with PCC, suggesting that the use of PCC for VKA reversal in ICH is sufficiently safe with respect to TEs. Explanations for the higher rate of TEs in VKA-ICH [19, 40] compared to inhomogeneous populations that received PCC due to different indications remain speculative. ICH patients are often multimorbid [47] and frequently immobilized [48] during the hospital stay, which comprises a high risk for thromboembolism. Moreover, uniform procedures to report TEs do not exist and causal assessment of TEs related to treatment with PCC is usually challenging. Patients with an indication for anticoagulation are already at an increased risk for systemic thromboembolisms and other comorbidities impede a clear attribution of TEs to PCC, for instance in case of MIs after PCC treatment in patients with coronary heart disease, and it remains unknown until when TEs caused by PCC treatment itself may occur. Moreover, the [16, 17, 19, 21, 38, 39, 43, 44] . Hence, it can be assumed, that these factors contribute to considerable differences of reported TEs after PCC treatment. According to our results, PCC doses between >2,000 and 3,000 IU were associated with TEs but a clear relationship between higher PCC dosing and development of TEs was not observed, as in the groups with even higher PCC doses, TEs were not detected more frequently. Reasons for this observation may be the small absolute number of TEs and the comparatively small number of patients who received particularly very high amounts of PCC (>3,000 IU PCC: 22 vs. 183 patients receiving <3,000 IU PCC). Nonetheless, our results suggest that higher PCC doses might be a risk for the development of TEs. Individual titration of PCC [49] to avoid exposure to unnecessarily high doses using point-of-care devices at the bedside is a potential option.
Our findings suggest that ICH patients with higher disease severity (i.e., NIHSS values >10 and hemorrhage volume ≥ 40 ml) and a restricted premorbid functional status (pmRS >2), indicating multimorbidity, more often suffered TEs after treatment with PCC. Hence, an approach of titrating PCC individually may be most beneficial particularly in these critically ill patients. On the other hand, the optimal procedure to prevent thromboembolism in this subgroup of ICH patients prone to develop TEs during the course of the hospital stay after INR reversal remains unknown [47, 50] . When caring for these patients, one should be aware of higher incidences of TEs in more severely affected VKA-ICH patients. Intermittent pneumatic compression of lower limbs or low-dose LMWH or unfractionated heparin, respectively, is currently recommended to prevent TEs [14] . Nevertheless, optimal measures to prevent TEs in this important subgroup of ICH patients remain unknown and should be evaluated in future studies.
The lack of a control group and the small number of TEs are limiting our results, and because adjustment for multiplicity was not performed, our results can only be interpreted descriptively. Late-onset TEs may have been underestimated because of the limited time of observation (median 6 days). Due to the retrospective characteristic, no standardized follow-up was performed. Moreover, body weight was not measured and no standardized ultrasound screening to detect clinical silent deep vein thrombosis was performed. However, we evaluated a large, homogenous group of patients with VKA-associated non-traumatic ICH and categorized all TE and allergic event carefully.
To conclude, reversal treatment in VKA-ICH with PCC appears safe. Though no clear relationship between higher PCC dosing and development of TEs was observed, PCC doses between >2,000 and 3,000 IU and higher morbidity at ICH onset was associated with TEs. Hence, individual titration of PCC to avoid exposure to unnecessarily high doses using point-of-care devices should be prospectively explored.
Disclosure Statement
None of the authors received any financial compensation for their contribution to this study. Dr. M. 
